Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr;10(4):225-38.
doi: 10.1038/nrneurol.2014.37. Epub 2014 Mar 18.

Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis

Affiliations
Review

Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis

Manuel A Friese et al. Nat Rev Neurol. 2014 Apr.

Abstract

Multiple sclerosis (MS) is the most frequent chronic inflammatory disease of the CNS, and imposes major burdens on young lives. Great progress has been made in understanding and moderating the acute inflammatory components of MS, but the pathophysiological mechanisms of the concomitant neurodegeneration--which causes irreversible disability--are still not understood. Chronic inflammatory processes that continuously disturb neuroaxonal homeostasis drive neurodegeneration, so the clinical outcome probably depends on the balance of stressor load (inflammation) and any remaining capacity for neuronal self-protection. Hence, suitable drugs that promote the latter state are sorely needed. With the aim of identifying potential novel therapeutic targets in MS, we review research on the pathological mechanisms of neuroaxonal dysfunction and injury, such as altered ion channel activity, and the endogenous neuroprotective pathways that counteract oxidative stress and mitochondrial dysfunction. We focus on mechanisms inherent to neurons and their axons, which are separable from those acting on inflammatory responses and might, therefore, represent bona fide neuroprotective drug targets with the capability to halt MS progression.

PubMed Disclaimer

References

    1. Nat Neurosci. 2002 Nov;5 Suppl:1039-42 - PubMed
    1. Brain Res. 2008 Oct 21;1236:206-15 - PubMed
    1. Nat Med. 2000 Jan;6(1):62-6 - PubMed
    1. Brain. 2011 Feb;134(Pt 2):571-84 - PubMed
    1. Proc Natl Acad Sci U S A. 1998 May 12;95(10):5768-72 - PubMed

Publication types